DK3458052T3 - Kombinationsbehandling af cancer - Google Patents

Kombinationsbehandling af cancer Download PDF

Info

Publication number
DK3458052T3
DK3458052T3 DK17726573.3T DK17726573T DK3458052T3 DK 3458052 T3 DK3458052 T3 DK 3458052T3 DK 17726573 T DK17726573 T DK 17726573T DK 3458052 T3 DK3458052 T3 DK 3458052T3
Authority
DK
Denmark
Prior art keywords
cancer
combination treatment
treatment
combination
Prior art date
Application number
DK17726573.3T
Other languages
English (en)
Inventor
Palle Christophersen
Jan Stenvang
Jens Lichtenberg
Annemette Thougaard
Nils Aage Brünner
Original Assignee
Scandion Oncology As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scandion Oncology As filed Critical Scandion Oncology As
Application granted granted Critical
Publication of DK3458052T3 publication Critical patent/DK3458052T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17726573.3T 2016-05-17 2017-05-17 Kombinationsbehandling af cancer DK3458052T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201670325 2016-05-17
PCT/EP2017/061823 WO2017198700A1 (en) 2016-05-17 2017-05-17 Combination treatment of cancer

Publications (1)

Publication Number Publication Date
DK3458052T3 true DK3458052T3 (da) 2020-02-03

Family

ID=58800797

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19205104.3T DK3622953T3 (da) 2016-05-17 2017-05-17 Kombinationsbehandling af cancer
DK17726573.3T DK3458052T3 (da) 2016-05-17 2017-05-17 Kombinationsbehandling af cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19205104.3T DK3622953T3 (da) 2016-05-17 2017-05-17 Kombinationsbehandling af cancer

Country Status (18)

Country Link
US (2) US11103481B2 (da)
EP (3) EP3854393A1 (da)
JP (1) JP7033554B2 (da)
CN (1) CN109475535A (da)
AU (1) AU2017266724B2 (da)
BR (1) BR112018073518A2 (da)
CA (1) CA3023202A1 (da)
CY (2) CY1122541T1 (da)
DK (2) DK3622953T3 (da)
ES (2) ES2870805T3 (da)
HR (2) HRP20200076T1 (da)
HU (2) HUE053744T2 (da)
LT (2) LT3622953T (da)
PL (2) PL3458052T3 (da)
PT (2) PT3622953T (da)
RS (2) RS59844B1 (da)
SI (2) SI3622953T1 (da)
WO (1) WO2017198700A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3622953T1 (sl) * 2016-05-17 2021-05-31 Scandion Oncology A/S Kombinirano zdravljenje raka
WO2019165158A1 (en) * 2018-02-22 2019-08-29 University Of Florida Research Foundation, Incorporated Il-6 inhibitors and methods of treatment
US20210251963A1 (en) * 2018-09-06 2021-08-19 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
WO2020079051A1 (en) 2018-10-16 2020-04-23 Scandion Oncology A/S Compounds for treatment of microbial infection
AU2022292074A1 (en) 2021-06-14 2023-12-14 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
WO2022263404A1 (en) 2021-06-14 2022-12-22 Scandion Oncology A/S Methods of increasing the plasma drug exposure of anticancer agents
EP4104834A1 (en) 2021-06-14 2022-12-21 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
TW202321205A (zh) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Sco-101的熱力穩定形式
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN117229258B (zh) * 2022-06-07 2024-07-19 杭州壹瑞医药科技有限公司 N-四唑基芳基脲类衍生物及其制备方法和应用
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
WO2024013058A1 (en) 2022-07-11 2024-01-18 Scandion Oncology A/S Salts of sco-101 and methods involving salts

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
TR199902593T2 (xx) 1997-04-22 2000-03-21 Neurosearch A/S �kame edilmi� fenil t�revleri, bunlar�n haz�rlanmas� ve kullan�m�.
BR9914638A (pt) 1998-10-22 2001-07-03 Neurosearch As Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
PL375318A1 (en) 2002-08-01 2005-11-28 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
WO2004111017A1 (en) 2003-06-17 2004-12-23 Neurosearch A/S Diphenylurea derivatives and their use as chloride channel blockers
DE602005015682D1 (de) 2004-02-04 2009-09-10 Neurosearch As Dimere azacyclische verbindungen und deren verwendung
CN101287456A (zh) 2004-12-17 2008-10-15 神经研究公司 用作钾通道激活剂的二苯基脲衍生物
KR20080103106A (ko) 2006-03-14 2008-11-26 뉴로서치 에이/에스 디페닐우레아 유도체 및 클로라이드 채널 차단제 또는 ＢＫＣａ 채널 조정자로서의 이의 용도
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
TWI508954B (zh) * 2012-04-27 2015-11-21 Nat Defense Medical Ct 雜環融合蒽醌衍生物、其製備方法與醫藥組合物
EP2919009B1 (en) 2014-03-10 2018-09-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft LRRC8 proteins and protein complexes and methods for identification of channel modulators
ES2662822T3 (es) 2015-03-04 2018-04-09 Scandion Oncology A/S Derivados de 4-amino-3-fenilamino-6-fenilpirazol[3,4-d]pirimidina para uso como inhibidores de la BCRP en tratamientos terapéuticos
SI3622953T1 (sl) * 2016-05-17 2021-05-31 Scandion Oncology A/S Kombinirano zdravljenje raka

Also Published As

Publication number Publication date
HRP20200076T1 (hr) 2020-04-03
US11103481B2 (en) 2021-08-31
SI3458052T1 (sl) 2020-04-30
EP3458052B1 (en) 2019-11-06
PT3622953T (pt) 2021-04-21
CA3023202A1 (en) 2017-11-23
CN109475535A (zh) 2019-03-15
JP7033554B2 (ja) 2022-03-10
CY1124242T1 (el) 2022-07-22
JP2019519506A (ja) 2019-07-11
HRP20210572T1 (hr) 2021-05-14
PL3622953T3 (pl) 2021-08-16
ES2770374T3 (es) 2020-07-01
WO2017198700A1 (en) 2017-11-23
BR112018073518A2 (pt) 2019-03-19
US20190269654A1 (en) 2019-09-05
EP3622953B1 (en) 2021-03-17
LT3458052T (lt) 2020-02-10
RS61786B1 (sr) 2021-06-30
PT3458052T (pt) 2020-02-03
US20210353596A1 (en) 2021-11-18
EP3622953A1 (en) 2020-03-18
AU2017266724B2 (en) 2022-04-14
EP3458052A1 (en) 2019-03-27
LT3622953T (lt) 2021-04-26
PL3458052T3 (pl) 2020-06-29
SI3622953T1 (sl) 2021-05-31
HUE053744T2 (hu) 2021-07-28
HUE047542T2 (hu) 2020-04-28
ES2870805T3 (es) 2021-10-27
DK3622953T3 (da) 2021-04-26
AU2017266724A1 (en) 2018-12-20
US11903927B2 (en) 2024-02-20
CY1122541T1 (el) 2021-01-27
RS59844B1 (sr) 2020-02-28
EP3854393A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3431105T3 (da) Medicinsk sammensætning til behandling af cancer
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3377516T3 (da) Sammensætning til behandling af cancer
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3474841T3 (da) Fremgangsmåder til behandling af ar+-brystkræft
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3166976T3 (da) Anti-pd-l1-kombinationer til behandling af tumorer
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3458610T3 (da) Terapeutisk behandling af brystcancer baseret på c-MAF-status
DK3439663T3 (da) Fremgangsmåder til behandling af pædiatriske cancere
DK3307267T3 (da) Behandling af multipel sklerose
DK3506904T3 (da) Behandling af demens
DK3353177T3 (da) Tricykliske heterocykler til behandling af cancer
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3400072T3 (da) Formuleringer til behandling af blærecancer